Company intelligence / Profile preview

Inflamax Research

Toronto, Ontario, Canadacliantha.com ↗

Ownership: Private
Employees: ~118
Development stage: Commercial

Overview

Inflamax Research specialized in conducting early and late phase clinical trials with a focus on inflammatory diseases, allergies, asthma, dry eye syndrome, and tobacco research. The company was recognized for its patented Environmental Exposure Chamber technology to simulate real-world allergen exposure. It supported numerous industry-sponsored studies including those on e-cigarettes and nicotine replacement therapies. In 2017, it was acquired by Cliantha Research; its Toronto operations continued under the original leadership post-acquisition.

Therapeutic areas: OphthalmologyImmunologyPsychiatryPulmonology
Modalities: DeviceSmall molecule
Industry: Contract Research Organization

Partnerships

JUUL Labs Inc.RAI Services Co.Niconovum USA Inc.

Beyond the preview

Go deeper on Inflamax Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflamax Research.

Explore the full profile